Unleashing nature’s manufacturing powerhouse.
B cells are nature’s exquisitely tuned medicine factories, manufacturing proteins to fight disease and maintain health. What if… we could engineer these cells to produce any therapeutic protein needed … allogeneically, without preconditioning, and re-dosably? The resulting new class of medicines – Engineered B Cell Medicines (BCMs) – could be transformative.
Powerful & Durable
In nature, a single B cell can produce thousands of proteins per second at constant levels over decades. Leveraging this inherent power, our BCMs could create previously impossible options for patients.
Precisely Engineered
B cells resist interference by outside agents and have been notoriously intractable to therapeutically relevant engineering. Until now. Our tunable, site-specific, precision genome engineering results in BCMs that produce proteins efficiently, with controlled, constant and consistent dosing (and re-dosing).
Easily Administered
Plasma cells, terminally differentiated B cells, have evolved to be able to more easily evade immune detection, and they intrinsically traffic to and engraft in the bone marrow. These properties drive the potential for powerful off-the-shelf medicines without the need for the toxic preconditioning required in other classes of cellular medicine.
Exceptionally Versatile
BCMs can be engineered to produce a vast array of therapeutically important biologics without the burdens of other cellular medicines, driving exceptionally broad therapeutic application — across protein classes, patient populations, and therapeutic areas.
Scientific Publications
Molecular Therapy|February 6, 2025
In vivo tracking of ex-vivo-generated 89Zr-oxine-labeled plasma cells by PET in a non-human primate model
ASH 2024|December 8, 2024
